104 related articles for article (PubMed ID: 38717457)
1. Clinical and pathological characteristics of renal cell carcinomas with MiTF translocation.
Filler T; Verkarre V; Peyrottes A; Poinard F; Lupo A; Dariane C; Hurel S; Timsit MO; Mejean A; Audenet F
Fr J Urol; 2024 Mar; 34(2):102569. PubMed ID: 38717457
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract][Full Text] [Related]
3. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
[TBL] [Abstract][Full Text] [Related]
5. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
6. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
7. The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients.
Stoehr CG; Walter B; Denzinger S; Ghiorzo P; Sturm RA; Hinze R; Moch H; Junker K; Hartmann A; Stoehr R
Pathobiology; 2016; 83(4):165-9. PubMed ID: 26999813
[TBL] [Abstract][Full Text] [Related]
8. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
9. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
10. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
11. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
12. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
[TBL] [Abstract][Full Text] [Related]
13. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma.
Shimazui T; Kojima T; Yoshikawa K; Ami Y; Oikawa T; Uchida K; Akaza H
Cancer Sci; 2009 Sep; 100(9):1714-8. PubMed ID: 19496784
[TBL] [Abstract][Full Text] [Related]
14. Oncologic outcomes of nephron-sparing surgery in patients with T1 multifocal renal cell carcinoma.
Li G; Zhu D; Gao H; Chen H; Li Y; Niu Y
Clin Transl Oncol; 2019 Jun; 21(6):760-765. PubMed ID: 30443869
[TBL] [Abstract][Full Text] [Related]
15. Nephron-sparing surgery in the treatment of pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions.
Liu C; Zhang W; Song H
J Pediatr Surg; 2017 Sep; 52(9):1492-1495. PubMed ID: 28365106
[TBL] [Abstract][Full Text] [Related]
16. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
[TBL] [Abstract][Full Text] [Related]
17. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney.
Lau WK; Blute ML; Weaver AL; Torres VE; Zincke H
Mayo Clin Proc; 2000 Dec; 75(12):1236-42. PubMed ID: 11126830
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
19. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
[TBL] [Abstract][Full Text] [Related]
20. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.
Leibovich BC; Blute M; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2004 Mar; 171(3):1066-70. PubMed ID: 14767272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
